{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:55:28Z","timestamp":1791424528523,"version":"4.3.3"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100001755","name":"Mesothelioma Applied Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>We demonstrated previously that autologous tumor lysate\u2013pulsed dendritic cell\u2013based immunotherapy in patients with malignant pleural mesothelioma is feasible, well-tolerated, and capable of inducing immunologic responses against tumor cells. In our murine model, we found that reduction of regulatory T cells with metronomic cyclophosphamide increased the efficacy of immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the decrease in number of peripheral blood regulatory T cells during combination therapy of low-dose cyclophosphamide and dendritic cell immunotherapy and determine the induction of immunologic responses with this treatment in patients with mesothelioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ten patients with malignant pleural mesothelioma received metronomic cyclophosphamide and dendritic cell\u2013based immunotherapy. During the treatment, peripheral blood mononuclear cells were analyzed for regulatory T cells and immunologic responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Administration of dendritic cells pulsed with autologous tumor lysate combined with cyclophosphamide in patients with mesothelioma was safe, the only side effect being moderate fever. Dendritic cell vaccination combined with cyclophosphamide resulted in radiographic disease control in 8 of the 10 patients. Overall survival was promising, with 7 out of 10 patients having a survival of greater than or equal to 24 months and two patients still alive after 50 and 66 months. Low-dose cyclophosphamide reduced the percentage of regulatory T cells of total CD4 cells in peripheral blood from 9.43 (range, 4.34\u201326.10) to 4.51 (range, 0.27\u201310.30) after 7 days of cyclophosphamide treatment (P\u2009=\u20090.02).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Consolidation therapy with autologous tumor lysate\u2013pulsed dendritic cell\u2013based therapy and simultaneously reducing the tumor-induced immune suppression is well-tolerated and shows signs of clinical activity in patients with mesothelioma.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT 01241682).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201508-1573oc","type":"journal-article","created":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T10:32:35Z","timestamp":1450089155000},"page":"1023-1031","source":"Crossref","is-referenced-by-count":94,"title":["Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma"],"prefix":"10.1093","volume":"193","author":[{"given":"Robin","family":"Cornelissen","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P. J. J.","family":"Hegmans","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander P. W. M.","family":"Maat","sequence":"additional","affiliation":[{"name":"Department of Cardio-Thoracic Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaretha E. H.","family":"Kaijen-Lambers","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Bezemer","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudi W.","family":"Hendriks","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk C.","family":"Hoogsteden","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim G. J. V.","family":"Aerts","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and"},{"name":"Department of Pulmonary Medicine, Amphia Hospital, Breda, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,5,1]]},"reference":[{"key":"2026032100045623900_bib1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/ejcts\/ezr192","article-title":"Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma","volume":"41","author":"Nakas","year":"2012","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026032100045623900_bib2","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/bjc.2014.478","article-title":"Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales","volume":"111","author":"Linton","year":"2014","journal-title":"Br J Cancer"},{"key":"2026032100045623900_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"2026032100045623900_bib4","doi-asserted-by":"crossref","first-page":"927240","DOI":"10.1155\/2012\/927240","article-title":"New roads open up for implementing immunotherapy in mesothelioma","volume":"2012","author":"Cornelissen","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2026032100045623900_bib5","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100045623900_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coph.2014.06.007","article-title":"Immunomodulation in cancer","volume":"17","author":"Hegmans","year":"2014","journal-title":"Curr Opin Pharmacol"},{"key":"2026032100045623900_bib7","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur Respir J"},{"key":"2026032100045623900_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12307-012-0100-4","article-title":"The role of regulatory T cells in mesothelioma","volume":"5","author":"Ireland","year":"2012","journal-title":"Cancer Microenviron"},{"key":"2026032100045623900_bib9","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"2026032100045623900_bib10","first-page":"5363","article-title":"Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro","volume":"32","author":"Kan","year":"2012","journal-title":"Anticancer Res"},{"key":"2026032100045623900_bib11","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/798467","article-title":"Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity","volume-title":"J Biomed Biotechnol","author":"Veltman","year":"2010"},{"key":"2026032100045623900_bib12","article-title":"Dentritic cell based immunotherapy in combination with metronomic cyclophosphamide in patients with mesothelioma","author":"Aerts","year":"2012"},{"key":"2026032100045623900_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"2026032100045623900_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"key":"2026032100045623900_bib15","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey","volume":"75","author":"Zucali","year":"2012","journal-title":"Lung Cancer"},{"key":"2026032100045623900_bib16","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/1756-0500-5-482","article-title":"Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience","volume":"5","author":"Bearz","year":"2012","journal-title":"BMC Res Notes"},{"key":"2026032100045623900_bib17","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.jtcvs.2007.02.014","article-title":"Ten traps for the unwary in surgical series: a case study in mesothelioma reports","volume":"133","author":"Treasure","year":"2007","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026032100045623900_bib18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/JTO.0000000000000064","article-title":"Does surgery improve survival of patients with malignant pleural mesothelioma? A multicenter retrospective analysis of 1365 consecutive patients","volume":"9","author":"Bovolato","year":"2014","journal-title":"J Thorac Oncol"},{"key":"2026032100045623900_bib19","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1158\/0008-5472.CAN-05-0328","article-title":"Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy","volume":"65","author":"Broomfield","year":"2005","journal-title":"Cancer Res"},{"key":"2026032100045623900_bib20","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.4049\/jimmunol.1102209","article-title":"Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients","volume":"187","author":"Alfaro","year":"2011","journal-title":"J Immunol"},{"key":"2026032100045623900_bib21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00262-011-1106-3","article-title":"Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome","volume":"61","author":"Ge","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"2026032100045623900_bib22","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00262-012-1242-4","article-title":"Metastatic melanoma patients treated with dendritic cell vaccination, interleukin-2 and metronomic cyclophosphamide: results from a phase II trial","volume":"61","author":"Ellebaek","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"2026032100045623900_bib23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00262-011-1081-8","article-title":"Phase I\/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission","volume":"61","author":"Chu","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"2026032100045623900_bib24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00281-011-0245-0","article-title":"Immunomodulatory effects of cyclophosphamide and implementations for vaccine design","volume":"33","author":"Sistigu","year":"2011","journal-title":"Semin Immunopathol"},{"key":"2026032100045623900_bib25","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"key":"2026032100045623900_bib26","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.immuni.2014.12.006","article-title":"Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4","volume":"41","author":"Wing","year":"2014","journal-title":"Immunity"},{"key":"2026032100045623900_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"2026032100045623900_bib28","first-page":"999","article-title":"Metabolic response of non-Hodgkin\u2019s lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET","volume":"41","author":"Torizuka","year":"2000","journal-title":"J Nucl Med"},{"key":"2026032100045623900_bib29","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00262-006-0265-0","article-title":"[F-18]-Fluoro-2-deoxy-D: -glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model","volume":"56","author":"Chaise","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"2026032100045623900_bib30","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00345-011-0723-y","article-title":"Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma","volume":"31","author":"Gilles","year":"2013","journal-title":"World J Urol"},{"key":"2026032100045623900_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2013.12.005","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Nishikawa","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"2026032100045623900_bib32","doi-asserted-by":"crossref","first-page":"e87705","DOI":"10.1371\/journal.pone.0087705","article-title":"Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab","volume":"9","author":"Tarhini","year":"2014","journal-title":"PLoS One"},{"key":"2026032100045623900_bib33","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/mt.2009.309","article-title":"A phase I trial of repeated intrapleural adenoviral-mediated interferon-\u03b2 gene transfer for mesothelioma and metastatic pleural effusions","volume":"18","author":"Sterman","year":"2010","journal-title":"Mol Ther"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/193\/9\/1023\/67267787\/ajrccm_193_9_1023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/193\/9\/1023\/67267787\/ajrccm_193_9_1023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:05:07Z","timestamp":1774065907000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/193\/9\/1023\/8508934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,1]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,5,1]]},"published-print":{"date-parts":[[2016,5,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201508-1573oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,5]]},"published":{"date-parts":[[2016,5,1]]}}}